Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. Its innovative, patented 3C Patch® System draws on the individual patient’s capacity to heal and is clinically proven to accelerate wound healing of chronic diabetic foot ulcers. Headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the Danish 2018 EY Entrepreneur of the Year Award in the life science category. Our business model is supported by high quality RCT evidence published in The Lancet in September 2018 and a 2019 IWGDF Recommendation. www.reapplix.com